SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Ventrus Biosciences, Inc. Completes Enrollment of Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease